THE EFFECTIVENESS OF COMBINED THERAPY OF POSTMENOPAUSAL OSTEOPOROSIS WITH DUAL ACTION DRUGS

T. B. Minasov , B. S. Minasov

Traumatology and Orthopedics of Russia ›› 2011, Vol. 17 ›› Issue (4) : 92 -94.

PDF
Traumatology and Orthopedics of Russia ›› 2011, Vol. 17 ›› Issue (4) : 92 -94. DOI: 10.21823/2311-2905-2011--4-92-94
Experience exchange
other

THE EFFECTIVENESS OF COMBINED THERAPY OF POSTMENOPAUSAL OSTEOPOROSIS WITH DUAL ACTION DRUGS

Author information +
History +
PDF

Abstract

Osteoporosis is one of the most dangerous diseases occurred in elderly persons. Results of application of strontium ranelate in combination with calcium for treatment a women with a postmenopausal osteoporosis are resulted. The influence of this complex therapy on dynamics of mineral density indexes of a bone tissue and the level of bone metabolism were studied. Strontium ranelate both at monotherapy, and in combination with calcium promotes the augmentation of mineral density of bone tissue in an axial skeleton. The taking Strontium ranelate doesn’t cause serious side effect.

Cite this article

Download citation ▾
T. B. Minasov, B. S. Minasov. THE EFFECTIVENESS OF COMBINED THERAPY OF POSTMENOPAUSAL OSTEOPOROSIS WITH DUAL ACTION DRUGS. Traumatology and Orthopedics of Russia, 2011, 17(4): 92-94 DOI:10.21823/2311-2905-2011--4-92-94

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Лесняк О.М. Фармакоэкономика средств профилактики и лечения остеопороза / О.М. Лесняк // Руководство по остеопорозу. - М., 2003. - С. 469-481.

[2]

Рожинская, Л.Я. Результаты Российского многоцентрового исследования эффективности стронция ранелата у женщин с постменопаузальным остеопорозом / Л.Я. Рожинская [и др.] //Остеопороз и остеопатии. - 2007. - № 3. - С. 25-30.

[3]

Шилин, Д.Е. Потребление кальция женщинами репродуктивного возраста: пилотное исследование в 27 субъектах Российской Федерации / Д.Е. Шилин, А.Д. Шилин, Л.В. Адамян // Тезисы докладов III Российского конгресса по остеопорозу с международным участием. - Екатеринбург, 2008. - С. 46.

[4]

Bonnick, S.L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? / S.L. Bonnick, L. Shulman // Am. J. Med. - 2006. - Vol. 119, N 4, Suppl. 1. - S. 25-31.

[5]

Bonnick, S. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density / S. Bonnick [et al.] // Cuop. Med. Res. Opin. - 2007. -Vol. 23, N 6. - P. 1341-1349.

[6]

Cummings, S.R. Epidemiology and outcomes of osteoporotic fractures / S.R. Cummings, L.J. Melton III // Lancet. - 2002. - Vol. 359. - P. 1761-1767

[7]

Delmas, P.D. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation / P.D. Delmas [et al.] // Osteoporos Int. - 2000. - Vol. 11, Suppl. 6. - S. 2-17.

[8]

Kanis, J.A. An update on the diagnosis and assessment of osteoporosis with densitometry / J.A. Kanis, C.C. Gluer // Osteoporosis Int. - 2000. -Vol. 11. - P. 192-202.

[9]

Kanis, J.A. A family history of fracture and fracture risk: a metaanalisys / J.A. Kanis [et al.] // Bone. - 2004. -Vol. 35, N 5. - P. 1029- 1037.

[10]

Kanis, J.A. European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women / J.A. Kanis [et al.] // Osteoporos Int. -2008. - Vol. 19, N 4. - P. 399-428.

AI Summary AI Mindmap
PDF

140

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/